Eponef 6000 Injection contains Recombinant Human Erythropoietin Alfa at a concentration of 10,000 IU/ml, a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not on dialysis, as well as anemia due to chemotherapy in cancer patients. Eponef 6000 enhances erythroid progenitor cell proliferation and differentiation in the bone marrow, thereby increasing hemoglobin levels and reducing the need for blood transfusions. The injection is administered subcutaneously or intravenously, with dosage individualized based on patient response and hemoglobin targets. Monitoring of hemoglobin levels, blood pressure, and iron status is essential during therapy to optimize efficacy and minimize adverse effects. Potential side effects include hypertension, thromboembolic events, and injection site reactions. Eponef 6000 should be used cautiously in patients with uncontrolled hypertension or hypersensitivity to erythropoietin products. Adequate iron supplementation is recommended to ensure optimal response. This product should be stored under refrigerated conditions and protected from light. Eponef 6000 Injection provides a vital therapeutic option for managing anemia in diverse clinical settings, improving patient quality of life and reducing transfusion-related risks.